Physician profile
Daniel Anghel
NPI 1033190046
$8,363.90
in general payments reported to CMS, 2019-2025
29 companies · $35.28 in 2025
The $35.28 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,151 · 2020: $1,025 · 2021: $1,691 · 2022: $1,768 · 2023: $579 · 2024: $115 · 2025: $35.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,364.95 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,304.29 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,161.42 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $968.77 | 2019-2024 | Xarelto |
| Abbvie INC. | $808.21 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $344.74 | 2019-2022 | |
| Pfizer INC. | $303.28 | 2019-2021 | |
| Novo Nordisk INC | $280.38 | 2019-2023 | |
| Allergan, INC. | $260.78 | 2019-2020 | |
| Amarin Pharma, INC. | $252.02 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $210.87 | 2019 | |
| Merck Sharp & Dohme LLC | $187.02 | 2019-2024 | Verquvo |
| Esperion Therapeutics, INC. | $144.22 | 2022 | |
| Amgen INC. | $126.82 | 2019 | |
| Mallinckrodt Enterprises LLC | $125.00 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $104.65 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.86 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $56.85 | 2019-2021 | |
| Lilly USA, LLC | $41.62 | 2019-2020 | |
| Medtronic, INC. | $35.28 | 2025 | Kyphon Express II Kyphopak Tray |
| Bardy Diagnostics, INC. | $31.26 | 2022 | |
| Cvrx, INC. | $28.53 | 2022 | |
| Gilead Sciences, INC. | $26.84 | 2019 | |
| Clarus Therapeutics INC. | $23.06 | 2021 | |
| Edwards Lifesciences Corporation | $21.25 | 2020 | |
| Vifor Pharma, INC. | $20.91 | 2019 | |
| Amryt Pharma Holdings Ltd | $19.42 | 2021 | |
| Irhythm Technologies, INC. | $13.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Anghel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.